This and similar findings have led to the currently running phase I/II trial in various NRG1 fusion-positive cancers of Zenocutuzumab, a novel, bispecific antibody binding both HER2 and HER3 and inhibiting NRG1 binding through a ‘Dock & Block®’ mechanism of action [85]. Here, ERBB2 is linked to cancer.